Allworth Financial
RLMD icon

Allworth Financial’s Relmada Therapeutics RLMD Stock Holding History

Allworth Financial’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8K Hold
2,000
– – ﹤0.01% 3490
2026
Q1 		$13.9K Hold
2,000
– – ﹤0.01% 3257
2025
Q4 		$9.66K Buy
+2,000
New +$6.7K ﹤0.01% 3295
2023
Q4 		– Sell
-89
Closed -$267 – 3592
2023
Q3 		$267 Sell
89
-69
-44% -$205 ﹤0.01% 3191
2023
Q2 		$389 Hold
158
– – ﹤0.01% 2945
2023
Q1 		$358 Buy
158
+69
+78% +$238 ﹤0.01% 2904
2022
Q4 		$311 Buy
+89
New +$782 ﹤0.01% 2727

Other funds holding RLMD

Jupiter Topco
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Allworth Financial's RLMD Position: Q2 2026 in Review

Allworth Financial held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 2,000 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3490.

Allworth Financial first reported a position in RLMD in Q4 2022 and has held it in 7 quarters since. The position peaked at $13.9K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Allworth Financial held 2,000 shares of Relmada Therapeutics worth $13.8K as of Q2 2026.
  • Allworth Financial left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3490 holding.
  • Allworth Financial first reported a position in Relmada Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • Allworth Financial's Relmada Therapeutics position peaked at $13.9K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.